MELANOPSIN VARIANTS FOR VISION RESTORATION
Provided herein, inter alia, are melanopsin variants that demonstrate greater amplitude/conductance and/or faster off kinetics than the amplitude/conductance and/or the off kinetics of the wild type human melanopsin. Also provided are related nucleic acids, virions, host cells, methods of producing recombinant virions, and pharmaceutical compositions. Further provided are methods of using such melanopsin variants to restore or enhance visual function in a subject.
1 . A melanopsin variant comprising no more than amino acids 1-425 of a wild type human melanopsin set forth in SEQ ID NO: 1, wherein amplitude/conductance and/or off kinetics of the melanopsin variant are greater than the amplitude/conductance and/or faster than the off kinetics of the wild type human melanopsin.
2 . The melanopsin variant of claim 1 , comprising the sequence set forth in any one of SEQ ID NOs: 2, 3, 4, 82, 83, and 84 or a variant thereof that comprises one or more amino acid substitutions.
3 . The melanopsin variant of claim 2 , wherein the variant comprises one or more amino acid substitution(s) at P10, T83, T129, Q135, S183, Y212, E215, M226, Y382, S384, R386, and/or R390, wherein amino acid position(s) are relative to the wild type human melanopsin set forth in SEQ ID NO: 1.
4 . The melanopsin variant of claim 3 , wherein the one or more substitution mutation(s) are selected from the group consisting of: P10F, T83L, T129S, Q135N, S183A, Y212F or Y212A, E215S, M226S or M226T, Y382E or Y382D, S384D, R386A, and R390A or R390D.
5 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the P10F substitution.
6 . The melanopsin variant of claim 5 , wherein the melanopsin variant comprises SEQ ID NO: 5.
7 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the T83L substitution.
8 . The melanopsin variant of claim 7 , wherein the melanopsin variant comprises SEQ ID NO: 6.
9 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the T129S substitution.
10 . The melanopsin variant of claim 9 , wherein the melanopsin variant comprises SEQ ID NO: 7.
11 . The melanopsin variant of claim 4 , comprising the Q135N substitution.
12 . The melanopsin variant of claim 11 , wherein the melanopsin variant comprises SEQ ID NO: 8 or 9.
13 . The melanopsin variant of claim 4 , comprising the S183A substitution.
14 . The melanopsin variant of claim 13 , wherein the melanopsin variant comprises any one of SEQ ID NOs: 10-12.
15 . The melanopsin variant of claim 4 , comprising the Y212F substitution.
16 . The melanopsin variant of claim 15 , wherein the melanopsin variant comprises SEQ ID NO: 13.
17 . The melanopsin variant of claim 4 , comprising the M226S or the M226T substitution.
18 . The melanopsin variant of claim 17 , wherein the melanopsin variant comprises SEQ ID NO: 14 or 15.
19 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the Y382E or the Y382D substitution.
20 . The melanopsin variant of claim 19 , wherein the melanopsin variant comprises SEQ ID NO: 16.
21 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the S384D substitution.
22 . The melanopsin variant of claim 21 , wherein the melanopsin variant comprises SEQ ID NO: 17.
23 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the R386A substitution.
24 . The melanopsin variant of claim 23 , wherein the melanopsin variant comprises SEQ ID NO: 18 or 19.
25 . The melanopsin variant of claim 4 , wherein the melanopsin variant comprises the R390A or the R390D substitution.
26 . The melanopsin variant of claim 25 , wherein the melanopsin variant comprises any one of SEQ ID NOs: 20-23.
27 . A melanopsin variant comprising at least amino acids 1-377 of a wild type human melanopsin set forth in SEQ ID NO: 1 fused to a c-terminal domain (CTD) of a heterologous G protein-coupled receptor (GPCR) or a CTD variant thereof, wherein amplitude/conductance and/or off kinetics of the melanopsin variant are greater than the amplitude/conductance and/or faster than the off kinetics of the wild type human melanopsin.
28 - 34 . (canceled)
35 . A melanopsin variant comprising one or more amino acid substitutions at P10, T83, T129, Q135, S183, Y212, E215, M226, Y382, S384, R386, and R390, wherein amino acid positions are relative to a wild type human melanopsin set forth in SEQ ID NO: 1, and wherein amplitude/conductance and/or off kinetics of the melanopsin variant are greater than the amplitude/conductance and/or faster the off kinetics of the wild type human melanopsin.
36 - 38 . (canceled)
39 . A nucleic acid comprising a polynucleotide sequence that encodes the melanopsin variant of claim 1 .
40 . The nucleic acid of claim 39 , operably linked to a retinal cell-specific promoter, wherein the retinal cell-specific promoter is selected from the group consisting of: human synapsin (hSyn), SNCG, NEFH, NEFL, 4×grm6, and grm6.
41 - 42 . (canceled)
43 . The nucleic acid of claim 39 , further comprising one or more enhancer sequences, intron sequences, leader sequences, Kozak sequences, poly A sequences, stuffer sequences, and/or inverted terminal repeat (ITR) sequences.
44 . A recombinant virion comprising:
(a) a capsid protein and
(b) the nucleic acid of claim 39 .
45 . The recombinant virion of claim 44 , wherein the capsid protein is selected from: AAV2-7m8, AAV2, AAV2-4YF, AAV9, AAV9-7m8, R100 and LSV1.
46 . A host cell comprising the nucleic acid of claim 39 .
47 . The host cell of claim 46 , further comprising one or more of:
(i) a polynucleotide encoding a capsid protein;
(ii) a polynucleotide encoding a rep protein; and
(iii) AAV helper functions
48 . A method for producing a recombinant virion, comprising:
(a) culturing the host cell of claim 46 under conditions to produce the recombinant virion,
(b) recovering the recombinant virion produced by the host cell, and
(c) purifying the recombinant virion.
49 . (canceled)
50 . A pharmaceutical composition comprising the recombinant virion of claim 44 and a pharmaceutically acceptable excipient.
51 . A method of restoring or enhancing visual function in a subject, comprising administering the pharmaceutical composition of claim 50 to the eye of the subject.
52 . The method of claim 51 , wherein the administration comprises an intraocular injection, a subretinal injection, a suprachoroidal injection, or an intravitreal injection.
53 . The method of claim 51 , wherein:
i) the subject has an ocular disease or disorder selected from the group consisting of: retinitis pigmentosa, macular degeneration, retinoschisis, Leber's Congenital Amaurosis, diabetic retinopathy, geographic atrophy, choroideremia, cone dystrophy, and cone-rod dystrophy; or
ii) the subject has experienced retinal detachment or photoreceptor loss due to ocular disease, infection, trauma, injury, impact to the head, acute light damage, UV light damage, laser damage, or chemical damage.
54 . (canceled)